鸽副黏病毒Ⅰ型(川沙株)攻毒剂量研究

为了确定鸽副黏病毒Ⅰ型灭活疫苗(S-1株)攻毒试验的攻毒剂量。本研究采用SPF鸡胚测定鸽副黏病毒Ⅰ型强毒株(川沙株)E5代的病毒含量,并以不同剂量病毒液分别接种30日龄低抗体幼龄鸽(HI抗体≤2)和120日龄低抗体青年鸽(HI抗体≤2),对试验鸽进行临床症状和病理学检查。结果显示,该病毒株对低抗体鸽有致死作用,最小致死量为102.5 ELD50。因此,为了确保攻毒效果,在鸽副黏病毒Ⅰ型灭活疫苗(S-1株)制造及检验规程中规定:以1 000倍的最小致死量(即105.5 ELD50)作为疫苗免疫效力检验的攻毒剂量。     

猪繁殖与呼吸综合征病毒嵌合感染性克隆的构建和应用

高致病性猪蓝耳病近年来在我国广泛流行,目前尚无高效疫苗用于该病的防制.本研究以PRRSV弱毒感染性克隆-pAPRRS作为主要骨架,将高致病性猪蓝耳病病毒江西分离株(JX143)的主要结构蛋白基因(ORF4-7)以及3'UTR区域替换入pAPPRS相应编码区域,构建了pSX12(ORF4-7-3'UTR)、p5NX12(ORF5-7-3'UTR)以及p56N12(ORF5-6)三个PRRSV全长嵌合克隆.经DNA转染Marc-145细胞后拯救出嵌合病毒,并对拯救病毒进行了病毒生物学特性的分析;选取拯救病毒v56N12(ORF5-6)和vSX12(ORF4-7-3'UTR)免疫29日龄猪进行免疫原性试验,结果表明,以v56N12免疫后抗体水平相对较低,故免疫原性相对较差;而vSX12病毒免疫后14d血清ELISA抗体达到阳性值(IDEXXELISA值s/p>0.4),免疫后28d中和抗体效价从原来的1:5以下上升到1:15以上,说明vSX12具有良好的免疫原性并可进行免疫监测;免疫后28 d以强毒JX143株攻毒,结果vSX12免疫组未见发病,而未免疫攻毒对照组全部发病并有1头死亡,vSX12免疫猪攻毒后病毒血症持续6d后消失.而对照组攻毒后至少持续13 d,说明vSX12可对高致病性猪蓝耳病提供有效的免疫保护.本研究构建的三个嵌合病毒为开发同时抗经典和变异株PRRSV感染的二价疫苗,以及探寻高致病性猪蓝耳病病毒的毒力因子奠定了基础.     

鸭甲肝病毒1型和3型间接ELISA方法的建立与应用

【目的】研究鸭甲肝病毒(Duck hepatitis A virus,DHAV)1型VP3和3型VP1串联基因在大肠杆菌中的表达,并以纯化的重组蛋白为抗原建立鸭病毒性肝炎抗体检测的间接ELISA方法。【方法】设计2对特异性引物,提取鸭甲肝病毒1型(DHAV-1)和3型(DHAV-3)的RNA,分别RT-PCR扩增得到714bp的DHAV-1VP3和720bp的DHAV-3 VP1基因,并克隆至p MD18-T载体中,然后依次将DHAV-1 VP3和DHAV-3 VP1定向插入p ET-32a(+)表达载体,获得重组表达载体p ET-1VP3-3VP1,进行IPTG(Isopropyl-beta-D-1-thiogalactopyranoside)诱导表达分析,以纯化的重组蛋白为抗原建立间接ELISA方法并应用于临床。【结果】经IPTG诱导表达,在大肠杆菌中可稳定、高效地表达DHAV-1VP3-3VP1蛋白。Western blot检测结果表明,表达的重组蛋白与DHAV-1和DHAV-3阳性血清均能发生特异性反应。确定间接ELISA方法的抗原最佳包被浓度为1.0μg/孔,血清最佳稀释度为1∶200,临界值为OD6 50值≥0.38,建立的间接ELISA方法具有较好的敏感性、特异性和重复性。该方法与中和试验分别检测DHAV-3阳性血清,两种方法的符合率各为96.3%和96.7%;初步临床应用结果表明该方法可用于雏鸭母源抗体和免疫后抗体的消长变化的检测。【结论】以大肠杆菌表达的DHAV-1VP3-3VP1重组蛋白建立的间接ELISA方法可用于DHAV-1和DHAV-3抗体的检测。     

共表达H5N1、H7N1亚型AIV HA与鸡IL-18多价重组鸡痘病毒免疫保护性研究

用本实验室构建的重组鸡痘病毒rFPV-H5HA-IL18、rFPV-H5HA-H7HA-IL18和rFPV-H5HA,经翼蹼免疫1日龄SPF鸡和7日龄商品Leghorn蛋鸡,同时以H5亚型AIV全病毒灭活疫苗作为对照.免疫后测定HI抗体效价、淋巴细胞转化指标、重组疫苗对增重的影响、免疫后的攻毒保护效力、免疫后的抑制排毒情况.免疫后不同时间分别测定特异性抗体和淋巴细胞刺激指数.试验结果表明,3株重组鸡痘病毒株均能诱导鸡体产生血凝抑制抗体（HI）;共表达鸡IL-18的rFPV-H5HA-IL18和rFPV H5HA-H7HA-IL18诱导商品蛋鸡的细胞免疫水平明显高于非共表达鸡IL-18的rFPV-H5HA.重组鸡痘疫苗免疫SPF和商品蛋鸡后第21d进行攻毒实验,rFPV-H5HA-IL18和rFPV-H5HA-H7HA-IL18免疫攻毒保护率达10/10,rFPV-H5HA免疫攻毒保护率达9/10,与常规疫苗相当.免疫的商品蛋鸡于攻毒后7d采集泄殖腔棉试子样品,检测排毒情况.结果表明,rFPV-H5HA-IL18、rFPV-H5HA-H7HA-IL18免疫组在攻毒后第7d无排毒,其抑制免疫鸡排毒效果优于常规疫苗和单独表达HA的rFPV-H5HA重组鸡痘病毒.rFPV-H5HA-IL18和rFPV-H5HA-H7HA-IL18免疫组鸡,在14日龄时的体重明显高于rFPV-H5HA免疫组和常规疫苗对照免疫组,表明共表达的鸡IL-18能降低鸡痘病毒载体对雏鸡增重的影响.     

基于响应面分析的高抗原活性鸭疫里默氏杆菌疫苗培养基的研制及其效果评价

【背景】鸭疫里默氏杆菌广泛存在于养殖场,引起雏鸭发生传染性浆膜炎,严重危害养鸭业的发展。【目的】提高鸭疫里默氏杆菌发酵培养水平和抗原活性,为鸭疫里默氏杆菌灭活疫苗的研制提供技术指引。【方法】利用单因素及响应面的试验设计方法,针对鸭疫里默氏杆菌进行疫苗培养基的研制,并探究不同发酵时间点该菌的抗原活性,选择抗原活性最高点时制备灭活疫苗,通过动物免疫保护试验评价疫苗免疫效果。【结果】使用研制的疫苗培养基发酵培养鸭疫里默氏杆菌,其活菌数能够达到4.68×1010 CFU/mL,较市面上该菌专用的培养基提高2.29倍。该菌发酵12 h后抗原活性达到最高,在此时制备的灭活疫苗诱导小鼠产生的抗体水平显著高于商品化灭活疫苗,攻毒保护率达到了100%。【结论】本研究研制的培养基具有优异的增菌效果,可作为生产鸭疫里默氏杆菌灭活疫苗抗原的发酵培养基,疫苗生产过程中可选择菌株抗原活性达到最高时收集菌体。     

表达猪瘟病毒E2蛋白的重组腺病毒的构建及其在兔体内的免疫原性分析

为了构建猪瘟重组腺病毒载体疫苗,通过细菌内同源重组法构建了含有猪瘟病毒E2基因的重组腺病毒rAdV-E2.测定其一步生长曲线,同时用间接免疫荧光试验和Western blotting检测外源基因表达,然后用rAdV-E2免疫家兔,免疫后6周用猪瘟兔化弱毒疫苗株(c株)进行攻击,攻毒后3 d取其脾脏,用实时荧光定量RT-PCR检测C株病毒RNA.结果表明,该重组腺病毒传至第10代时,毒价可达1.0×1010TCID<,50/mL;外源基因可在其中得到稳定表达;rAdV-E2接种兔免疫后2周产生猪瘟特异性抗体,免疫后5 W抗体达到峰值,攻毒后rAdV-E2接种兔和C株接种兔均未出现定型热反应,从其脾脏也未检测到C株病毒RNA,而野生型腺病毒接种兔均出现了定型热反应,并且从其脾脏检测大量C株病毒RNA,其含量达到了103拷贝/μL以上.由此表明,rAdV-E2可望开发为猪瘟候选疫苗.     

季节性和大流行性H1N1流感血凝素DNA疫苗电穿孔免疫小鼠及攻毒保护实验

在流感病毒疫苗中,DNA疫苗有望成为常规疫苗的替代品.研究构建了两个分别编码A/New Caledonia/20/99（H1N1）和A/California/04/2009（H1N1）流感病毒株血凝素抗原的DNA疫苗pV1A5和pVEH1,目的抗原经验证能够正确表达后,利用小鼠模型通过电穿孔方法肌肉注射免疫进行疫苗免疫效力评价.采用血凝抑制实验和酶联免疫吸附实验对免疫小鼠的血清进行血凝素特异性抗体检测,对血凝素特异性的T淋巴细胞经IFN-γ酶联免疫斑点实验进行检测.然后选择小鼠适应株A/NewCaledonia/20/99（H1N1）100个半数致死剂量对候选疫苗免疫的小鼠攻毒并监测生存率和体重变化率,以此评价疫苗保护效力.两疫苗组免疫小鼠T淋巴细胞和体液免疫水平显著高于pVAX1空载体对照组（P〈0.05）.此外,pV1A5组能够100%保护免疫小鼠抵抗100致死剂量同源病毒小鼠适应株的攻毒,而同种病毒下pVEH1组只有40%的保护率.结果表明,本实验构建的季节性流感DNA疫苗能够对同源病毒攻毒提供完全保护,而大流行流感株DNA疫苗只能部分抵抗季节性流感病毒.     

流行性乙型脑炎病毒减毒株免疫仔猪血清学反应和流行病学保护

1. 用乙脑病毒的减毒株C株和强毒株P,株免疫仔猪,接种P,株后48和72小时从仔猪血液中可检出病毒,用C株免疫的动物,检查病毒血症全属阴性。 2. 免疫前后检查和比较血清抗体的结果是：用P3株免疫的两只仔猪,免疫后抗体比免疫前明显增长;用C株疫苗10毫升和1.0毫升各免疫6只的两组动物中,免疫后分别有5只和2只抗体明显增长;接受灭活疫苗的6只动物,抗体全未增长。 3. 比较各组动物免疫前后血清抗体水平(见表2)还发现,对照组和灭活疫苗组内各有两只、C株疫苗10毫升免疫组内有一只动物,免疫后较免疫前的抗体水平反而有所降低。此种降低显然是母体被动抗体水平随年龄增大而下降的表现。 4. 在乙脑流行季节,从各组动物体内连续采取血管末梢血液,分离自然界散布的野生乙脑病毒,以观察流行病学保护效果。从对照组动物10只中有5只、灭活疫苗组6只中的2只分离到了野生乙脑病毒;而在用c株免疫的两组共12只,用P|株免疫的2只中,没有得到乙脑病毒。这些数据可以说明,C株病毒可用于免疫仔猪以防止自然界乙脑病毒造成的病毒血症,使用剂量小到1．0毫升仍有效。     

共表达H5N1、H7N1亚型AIV HA与鸡IL-18多价重组鸡痘病毒免疫保护性研究

用本实验室构建的重组鸡痘病毒rFPV-H5HA-IL18、rFPV-H5HA-H7HA-IL18和rFPV-H5HA,经翼蹼免疫1日龄SPF鸡和7日龄商品Leghorn蛋鸡,同时以H5亚型AIV全病毒灭活疫苗作为对照.免疫后测定HI抗体效价、淋巴细胞转化指标、重组疫苗对增重的影响、免疫后的攻毒保护效力、免疫后的抑制排毒情况.免疫后不同时间分别测定特异性抗体和淋巴细胞刺激指数.试验结果表明,3株重组鸡痘病毒株均能诱导鸡体产生血凝抑制抗体(HI);共表达鸡IL-18的rFPV-H5HA-IL18和rFPV H5HA-H7HA-IL18诱导商品蛋鸡的细胞免疫水平明显高于非共表达鸡IL-18的rFPV-H5HA.重组鸡痘疫苗免疫SPF和商品蛋鸡后第21d进行攻毒实验,rFPV-H5HA-IL18和rFPV-H5HA-H7HA-IL18免疫攻毒保护率达10/10,rFPV-H5HA免疫攻毒保护率达9/10,与常规疫苗相当.免疫的商品蛋鸡于攻毒后7d采集泄殖腔棉试子样品,检测排毒情况.结果表明,rFPV-H5HA-IL18、rFPV-H5HA-H7HA-IL18免疫组在攻毒后第7d无排毒,其抑制免疫鸡排毒效果优于常规疫苗和单独表达HA的rFPV-H5HA重组鸡痘病毒.rFPV-H5HA-IL18和rFPV-H5HA-H7HA-IL18免疫组鸡,在14日龄时的体重明显高于rFPV-H5HA免疫组和常规疫苗对照免疫组,表明共表达的鸡IL-18能降低鸡痘病毒载体对雏鸡增重的影响.     

猪脾转移因子对La Sota株鸡新城疫弱毒疫苗的免疫增强作用

【目的】本文旨在研究猪脾转移因子（TF）对新城疫（ND）病毒弱毒疫苗La Sota株的免疫增强作用及机理,为兽医临床防控提供理论依据。【方法】以4种不同剂量La Sota疫苗株分别单独、与TF联合免疫SPF鸡,14 d后以ND病毒（NDV）参考强毒F₄₈E₉株(10^4.7 ELD₅₀)进行攻毒,采用蛋白质芯片技术测定鸡外周血IL-6、IL-10、IL-16和IL-21浓度,并以血凝抑制（HI）试验和荧光定量RT-PCR方法分别检测鸡ND HI抗体效价和F₄₈E₉株的病毒血症水平。【结果】攻毒保护试验表明,单独免疫10^5.17、10^4.17、10^3.17和10^2.17 EID₅₀剂量时疫苗攻毒保护率分别为100%、55%、0%和0%,半数保护量(PD₅₀)为12 023 EID₅₀;对应剂量联合免疫时疫苗攻...     

Complete genome sequence of a novel duck hepatitis a virus discovered in southern china

We report here the complete genomic sequence of a novel duck hepatitis A virus (DHAV) isolated from mixed infections with DHAV type 1 (DHAV-1) and DHAV-3 in ducklings in Southern China. The whole nucleotide sequence had the highest homology with the sequence of DHAV-3 (GenBank accession number DQ812093) (96.2%). To our knowledge, this is the first report of gene rearrangement between DHAV-1 and DHAV-3, and it will help to understand the epidemiology and molecular characteristics of duck hepatitis A virus in Southern China.     

Identification of a Conserved B-Cell Epitope on Duck Hepatitis A Type 1 Virus VP1 Protein

BackgroundThe VP1 protein of duck hepatitis A virus (DHAV) is a major structural protein that induces neutralizing antibodies in ducks; however, B-cell epitopes on the VP1 protein of duck hepatitis A genotype 1 virus (DHAV-1) have not been characterized.

Methods and Results

To characterize B-cell epitopes on VP1, we used the monoclonal antibody (mAb) 2D10 against Escherichia coli-expressed VP1 of DHAV-1. In vitro, mAb 2D10 neutralized DHAV-1 virus. By using an array of overlapping 12-mer peptides, we found that mAb 2D10 recognized phages displaying peptides with the consensus motif LPAPTS. Sequence alignment showed that the epitope ¹⁷³LPAPTS¹⁷⁸ is highly conserved among the DHAV-1 genotypes. Moreover, the six amino acid peptide LPAPTS was proven to be the minimal unit of the epitope with maximal binding activity to mAb 2D10. DHAV-1–positive duck serum reacted with the epitope in dot blotting assay, revealing the importance of the six amino acids of the epitope for antibody-epitope binding. Competitive inhibition assays of mAb 2D10 binding to synthetic LPAPTS peptides and truncated VP1 protein fragments, detected by Western blotting, also verify that LPAPTS was the VP1 epitope.

Conclusions and Significance

We identified LPAPTS as a VP1-specific linear B-cell epitope recognized by the neutralizing mAb 2D10. Our findings have potential applications in the development of diagnostic techniques and epitope-based marker vaccines against DHAV-1.     

Genetic variation of the VP1 gene of the virulent duck hepatitis A virus type 1 (DHAV-1) isolates in Shandong province of China

To investigate the relationship of the variation of virulence and the external capsid proteins of the pandemic duck hepatitis A virus type 1 (DHAV-1) isolates, the virulence, cross neutralization assays and the complete sequence of the virion protein 1 (VP1) gene of nine virulent DHAV-1 strains, which were isolated from infected ducklings with clinical symptoms in Shandong province of China in 2007–2008, were tested. The fifth generation duck embryo allantoic liquids of the 9 isolates were tested on 12-day-old duck embryos and on 7-day-old ducklings for the median embryonal lethal doses (ELD₅₀s) and the median lethal doses (LD₅₀s), respectively. The results showed that the ELD₅₀s of embryonic duck eggs of the 9 DHAV-1 isolates were between 1.9 × 10⁶/mL to 1.44 × 10⁷/mL, while the LD₅₀s were 2.39 × 10⁵/mL to 6.15 × 10⁶/mL. Cross-neutralization tests revealed that the 9 DHAV-1 isolates were completely neutralized by the standard serum and the hyperimmune sera against the 9 DHAV-1 isolates, respectively. Compared with other virulent, moderate virulent, attenuated vaccine and mild strains, the VP1 genes of the 9 strains shared 89.8%–99.7% similarity at the nucleotide level and 92.4%–99.6% at amino acid level with other DHAV-1 strains. There were three hypervariable regions at the C-terminus (aa 158–160, 180–193 and 205–219) and other variable points in VP1 protein, but which didn’t cause virulence of DHAV-1 change.     

Complete Genome Sequence of a Duck Hepatitis A Virus Type 3 Identified in Eastern China

We report here the complete genome sequence of a novel duck hepatitis A virus type 3 (DHAV-3) isolated from a dead Cherry Valley duckling in eastern China. The whole genomic nucleotide sequence and polyprotein amino acid sequence of the virus had higher homology with those of Chinese DHAV-3 isolates, medium homology with those of Korean DHAV-3 isolates, and the lowest homology with those of Vietnamese isolate DN2. The result indicated that the genetic evolution of DHAV-3 isolates had obvious geographical features.     

三株新城疫病毒强毒株的生物学特性及全基因组序列分析

2009～2011年从北方发病鸡群和鸭群中分离出3株新城疫病毒（Newcastle disease virus,NDV）。通过致病性指数测定及交叉血凝抑制试验初步分析了3个毒株的毒力和相互之间的同源性。选取鸡源分离株SDLY01与新城疫疫苗株（LaSota）进行了交叉保护试验,选取鸭源毒株SD03对樱桃谷鸭进行攻毒实验,同时设计引物对3个毒株进行了全基因组测序,并与36株NDV参考株进行了分子进化分析。结果表明3个分离株F蛋白裂解位点的氨基酸序列均为112R-R-Q-K-R-F117符合强毒株的序列特征,并与致病性指数测定结果相符。交叉血凝抑制试验发现3个分离株与疫苗株LaSota 的抗原同源性较低为82.5%～89.4%,两个鸡源分离株间的抗原同源性为90%,而鸭源毒株SD03与鸡源毒株SDSG01同源性为100%。交叉保护试验和攻毒实验结果显示传统的LaSota疫苗能对SDLY01流行株提供100%免疫保护,但第5天仍检测到排毒;鸭源毒株SD03对樱桃谷鸭不致病,但能检出排毒,排毒期最长为5d。全基因组测序与分析表明3个毒株基因组长度均为15192bp,属于基因Ⅶd型毒株,与同期流行的鹅源及鸭源NDV毒株之间全基因组核苷酸序列具有高度的同源性,揭示鸭源、鹅源NDV与鸡源NDV在遗传学和流行病学上密切相关。     

Duck Hepatitis A virus possesses a distinct type IV internal ribosome entry site element of picornavirus

Sequence analysis of duck hepatitis virus type 1 (DHV-1) led to its classification as the only member of a new genus, Avihepatovirus, of the family Picornaviridae, and so was renamed duck hepatitis A virus (DHAV). The 5' untranslated region (5' UTR) plays an important role in translation initiation and RNA synthesis of the picornavirus. Here, we provide evidence that the 651-nucleotide (nt)-long 5' UTR of DHAV genome contains an internal ribosome entry site (IRES) element that functions efficiently in vitro and within BHK cells. Comparative sequence analysis showed that the 3' part of the DHAV 5' UTR is similar to the porcine teschovirus 1 (PTV-1) IRES in sequence and predicted secondary structure. Further mutational analyses of the predicted domain IIId, domain IIIe, and pseudoknot structure at the 3' end of the DHAV IRES support our predicted secondary structure. However, unlike the case for the PTV-1 IRES element, analysis of various deletion mutants demonstrated that the optimally functional DHAV IRES element with a size of approximately 420 nt is larger than that of PTV-1 and contains other peripheral domains (Id and Ie) that do not exist within the type IV IRES elements. The domain Ie, however, could be removed without significant loss of activity. Surprisingly, like the hepatitis A virus (HAV) IRES element, the activity of DHAV IRES could be eliminated by expression of enterovirus 2A protease. These findings indicate that the DHAV IRES shares common features with type IV picornavirus IRES elements, whereas it exhibits significant differences from type IV IRESs. Therefore, we propose that DHAV possesses a distinct type IV IRES element of picornavirus.     

Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.

We report here on a series of vaccine trials to evaluate the effectiveness of an inactivated equine infectious anemia virus (EIAV) whole-virus vaccine and of a subunit vaccine enriched in EIAV envelope glycoproteins. The inactivated vaccine protected 14 of 15 immunized ponies from infection after challenge with at least 10(5) 50% tissue culture-infective doses of the homologous prototype strain of EIAV. In contrast, it failed to prevent infection in any of 15 immunized ponies that were challenged with the heterologous PV strain. Levels of PV virus replication and the development of disease, however, were significantly reduced in 12 of the 15 ponies so challenged. The subunit vaccine prevented infection from homologous challenge in four of four ponies tested but failed to prevent infection in all four challenged with the PV strain. Two of the four subunit vaccinates had more severe symptoms of equine infectious anemia than nonimmunized ponies infected in parallel. Both vaccines stimulated EIAV-specific cell-mediated immunity. The in vitro lymphoproliferative response was shown to be mediated by T lymphocytes and appeared to be indistinguishable from that induced by EIAV infection. Significant differences were observed in the in vivo lymphocyte responses following challenge with the two virus strains. While peripheral blood mononuclear cells from the inactivated virus vaccinates were equally stimulated by both the prototype and PV strains, the subunit vaccinates challenged with PV exhibited lower levels of spontaneous proliferation and serine esterase activity. This diminished cellular response to PV was correlated with more severe clinical disease in the same ponies. These studies demonstrate for the first time that both an EIAV inactivated whole-virus vaccine and a viral envelope glycoprotein-based subunit vaccine can provide protection against rigorous challenge levels of homologous virus but are unable to protect against similar challenge levels of a heterologous virus. Moreover, the data demonstrate that protection can be achieved in the absence of detectable levels of virus-specific neutralizing antibody in the vaccine recipients at the time of virus challenge. While vaccine-induced virus-specific cell-mediated immune responses were detected, their role in conferring protection was not obvious. Nevertheless, protection from disease appeared to be correlated with the induction of high levels of serine esterase activity following challenge. A significant observation is that while the whole-virus vaccine was usually capable of preventing or markedly moderating disease in the PV-infected ponies, the subunit vaccine appeared to have a high potential to enhance the disease induced by PV infection.(ABSTRACT TRUNCATED AT 400 WORDS)     

Propagation of vaccine strain of duck enteritis virus in a cell line of duck origin as an alternative production system to propagation in embryonated egg

Duck virus enteritis (DVE) also known as duck plague, is a viral infection of ducks caused by duck enteritis virus (DEV). The control of the disease is mainly done by vaccination with a chicken embryo-adapted live virus that is known to be poorly immunogenic and affords partial protection. Further, the risk of harboring other infectious agents in the embryo particularly the deadly and zoonotic avian influenza virus is also high. In this paper, we report propagation of a chicken embryo-adapted vaccine strain of duck enteritis virus in duck embryo fibroblast (DEF) cell line. Thirty serial passages were done in DEF cell that made the vaccine virus further attenuated which was tested in ducks. The growth behaviors of the virus in DEF cells were studied and at 30th passage level the virus titre was found to be 10^6.8 TCID₅₀/ml. Ducks were immunized with this virus and challenged after 21 days with high dose of virulent DEV. All the immunized ducks withstood challenge with no clinical symptoms in any of the ducks while all the control ducks died. DEF cell which is free from other infectious agents appears to be a good system for cultivation of duck enteritis virus vaccine strain.     

Zonal-Centrifuged Purified Duck Embryo Cell Culture Rabies Vaccine for Human Vaccination

Rabies virus produced in duck embryo cell culture was concentrated from volumes of 14 to 30 liters to 400 to 800 ml by zonal centrifugation. Virus titers of peak fractions were from 100- to 1,000-fold greater than those of the starting material. Vaccines were prepared by combining fractions with peak virus titers and diluting back to 10 times concentration. The resulting beta-propiolactone-inactivated vaccines, when prepared as lyophilized vaccines with AlPO(4) adjuvant diluents, were low in protein nitrogen (0.01 mg/ml), and three of four lots passed the National Institutes of Health potency test when tested as equivalent to a standard 10% suspension of duck embryo or mouse brain tissue vaccine. These vaccines also induced good sero-conversion in adult rabbits after a single 1-ml dose of vaccine. Guinea pigs sensitized with zonal-centrifuged purified duck embryo vaccine (with AlPO(4) adjuvant) did not exhibit anaphylactic shock reactions when challenged with homologous vaccine. Also, no anaphylactic shock reactions were observed when guinea pigs were sensitized with either a 10% experimental duck embryo vaccine or cell culture vaccine and then challenged with the zonal-purified vaccine. However, guinea pigs sensitized with cell culture or zonal-purified vaccine and then challenged with the 10% experimental vaccine did show slight transitory congestion. The 10% experimental whole duck embryo vaccine was responsible for all observed anaphylactic shock reactions whether homologous or heterologous.     

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

Vaccination of mice with a peptide corresponding to the extracellular part of M2 protein coupled to the immunodominant domain of hepatitis B core can protect mice from a lethal challenge with influenza A virus. As the extracellular part of M2 protein is highly conserved in all known human influenza A strains, such a vaccine may protect against all human influenza A strains, which would represent a major advantage over current vaccine strategies. The present study demonstrates that protection is mediated exclusively by Abs, a very important feature of a successful preventive vaccine. However, these Abs neither bind efficiently to the free virus nor neutralize virus infection, but bind to M2 protein expressed on the surface of virus-infected cells. The presence of NK cells is important for protection, whereas complement is not, supposing that protection is mediated via Ab-dependent, cell-mediated cytotoxicity. The absence of neutralizing Abs results in much weaker protection than that achieved by vaccination with UV-inactivated influenza virus. Specifically, whereas neutralizing Abs completely eliminate signs of disease even at high viral challenge doses, M2-specific Abs cannot prevent infection, but merely reduce disease at low challenge doses. M2-specific Abs fail to protect from high challenge doses, as vaccinated mice undergo lethal infection under these conditions. In conclusion, protection mediated by M2-hepatitis B core vaccine would be insufficient during the yearly epidemics, for which full protection is desirable, and overall is clearly inferior to protection achieved by immunization with classical inactivated viral preparations.